Description
Indication & Scope
Trametinib Tablets (Mekinist®) is selective MEK1/2 inhibitor. It inhibits MEK kinase downstream of BRAF, blocks abnormal MAPK signaling pathway, suppresses proliferation and induces apoptosis of BRAF-mutated tumor cells.
- Mechanism
Inhibit MEK1/2 kinases, block oncogenic MAPK signaling pathway - Drug class
Oral MEK-targeted film-coated tablets - Clinical use
BRAF V600 mutant melanoma, non-small cell lung cancer and anaplastic thyroid carcinoma
| Generic Name | Trametinib Tablets |
| Brand Name | Mekinist® |
| Ingredient | Trametinib |
| Dosage Form | Film-coated Tablets |
| Package | 2mg*30 tablets/box |
| Conditions Treated | Single-agent or combined with dabrafenib for unresectable/metastatic BRAF V600 mutation-positive melanoma; Adjuvant therapy for completely resected BRAF V600 mutation-positive melanoma; Combined with dabrafenib for unresectable/metastatic BRAF V600 mutation-positive non-small cell lung cancer |
| Taboos | Hypersensitivity to trametinib or excipients; pregnancy and lactation |
| Place of origin | Stein, Switzerland |
| Priscription Type | Prescription drug (Rx) |
| Storage Conditions | Seal and store below 25°C, avoid light and moisture |
| Manufacturer | Novartis Pharma Stein AG |
| Registration Authority | National Medical Products Administration (NMPA) |
| Approval number | HJ20190069 |
| Approval Date | September 10, 2024 |
| Shelf Life | 36 months |
How to use ?
Recommended Dose: Melanoma / NSCLC / anaplastic thyroid carcinoma: 2mg once daily continuous oral administration
Time: Take at the same time every day, empty stomach (1 hour before or 2 hours after meals), swallow whole without crushing/chewing
Interaction: Strong CYP3A4 inhibitors significantly increase trametinib exposure; strong CYP3A4 inducers reduce efficacy, avoid concomitant use
Side effects: Rash, dry skin, diarrhea, peripheral edema, fatigue, hypertension; severe risks: cardiomyopathy, retinal vein occlusion, interstitial lung disease, severe hemorrhage, secondary malignancies
Important Notice
This product shall only be used for post-exposure rabies prophylaxis by professional medical staff. It must be applied combined with rabies vaccine and injected via wound infiltration plus intramuscular routes as specified. Do not administer intravenously or alter the dosage at will. Hypersensitivity monitoring is required throughout the whole injection process.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What administration rule should be strictly followed when you take trametinib?
Take on an empty stomach 1 hour before or 2 hours after meals.
What molecular target does trametinib specifically inhibit?
MEK1 and MEK2 kinases.
Which drug is usually combined with Mekinist for BRAF-mutated tumors?
Dabrafenib.
What severe pulmonary toxicity needs immediate treatment?
Interstitial lung disease.
Mekinist® | Trametinib Tablets | Melanoma and NSCLC | DengYueRX
INN: Trametinib
Indications: Melanoma and NSCLC (Non-Small Cell Lung Cancer)
Dosage Form: Film-coated Tablets
Strength: 2mg/Tablet
Original price was: $2,394.96.$2,035.71Current price is: $2,035.71.
